United Therapeutics (UTHR) CEO Rothblatt Sells $5.5M of Stock
Key Points
- United Therapeutics Corporation Chairperson and CEO Martine A Rothblatt sold 9,500 shares on October 22, 2026, in a transaction worth about $5.5 million.
- After the trade, Martine A Rothblatt indirectly holds 324,443 $UTHR shares, down 2.84% from before the trade.
- The stock recently traded near $584.79, holding a market capitalization of roughly $25.08 billion with upcoming earnings expected on November 4, 2026.
- Several financial institutions adjusted their positions recently, while analysts from firms like RBC Capital and Leerink Partners maintain favorable views on the specialty drug maker.
Since the trade, $UTHR is down 0.5% to date (from the $584.79 close on Oct 22, 2026).
Get United Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $UTHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
United Therapeutics Corporation Chairperson and CEO Martine A Rothblatt sold 9,500 shares of the biotech firm on October 22, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
UTHR
United Therapeutics Corporation
Inside Martine A Rothblatt's United Therapeutics Trade
The executive executed the planned sale at an average price of $583.38 per share, bringing the total value of the transaction to roughly $5.54 million. Following this pre-arranged move under a Rule 10b5-1 trading plan, Rothblatt held 324,443 shares, representing a 2.84% reduction in her direct ownership stake.
Other Institutional Activity in United Therapeutics Corporation
Large investment firms have also made adjustments to their positions in the biotech firm. Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.63 billion. Renaissance Technologies, LLC reduced its stake by 78,271 shares to finish with 1,708,739 shares valued around $1.0 billion. Meanwhile, Jupiter Topco LLC expanded its position by 100%, adding 415,564 shares to hold 831,129 shares worth approximately $488.2 million.
United Therapeutics Corporation Stock Up 4.3%
Shares closed at $584.79 on October 22, 2026, and recently traded around that same level as of October 23, 2026. The stock sits below its 52-week high of $609.35 while trading well above its 50-day moving average of $517.66.
Recent Earnings
The company reported trailing twelve-month revenue of $3.15 billion alongside strong profitability metrics, with the next earnings report scheduled for November 4, 2026.
Insider Buying and Selling at United Therapeutics Corporation
Rothblatt completed four other planned sales earlier in October, including 9,500 shares sold on October 21 for about $5.32 million, 9,500 shares on October 20 for about $5.26 million, 9,500 shares on October 19 for roughly $5.16 million, and 9,500 shares on October 16 for around $5.08 million.
Analysts Set New Price Targets
Several Wall Street firms updated their views on the stock through October 2026. BTIG upgraded the shares to a buy rating with a $728.00 target on October 1. Morgan Stanley maintained its equal weight rating and raised its target from $515.00 to $566.00 on October 7. RBC Capital maintained an outperform rating while adjusting its target to $697.00 on October 22, following an earlier target of $708.00 on October 8. Leerink Partners maintained an outperform rating with a $725.00 target on October 19.
About United Therapeutics Corporation
United Therapeutics develops and commercializes specialized medical therapies targeting severe, chronic, and life-threatening conditions. The company focuses primarily on pulmonary hypertension and organ manufacturing initiatives to address critical unmet needs in healthcare.
Bottom Line
Investors will look toward the company's upcoming earnings report on November 4, 2026, for further operational updates. Future regulatory filings will provide additional insight into insider holdings and institutional portfolio adjustments.
Related Filing Alerts
Source: Martine A Rothblatt's Form 4 filing on $UTHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts